Cargando…
Ocrelizumab in Patients with Active Primary Progressive Multiple Sclerosis: Clinical Outcomes and Immune Markers of Treatment Response
Ocrelizumab is a B-cell-depleting monoclonal antibody approved for the treatment of relapsing-remitting multiple sclerosis (RRMS) and active primary progressive MS (aPPMS). This prospective, uncontrolled, open-label, observational study aimed to assess the efficacy of ocrelizumab in patients with aP...
Autores principales: | Boziki, Marina, Bakirtzis, Christos, Sintila, Styliani-Aggeliki, Kesidou, Evangelia, Gounari, Evdoxia, Ioakimidou, Aliki, Tsavdaridou, Vasiliki, Skoura, Lemonia, Fylaktou, Asimina, Nikolaidou, Vasiliki, Stangou, Maria, Nikolaidis, Ioannis, Giantzi, Virginia, Karafoulidou, Eleni, Theotokis, Paschalis, Grigoriadis, Nikolaos |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9222195/ https://www.ncbi.nlm.nih.gov/pubmed/35741088 http://dx.doi.org/10.3390/cells11121959 |
Ejemplares similares
-
Blood Metabolomics May Discriminate a Sub-Group of Patients with First Demyelinating Episode in the Context of RRMS with Increased Disability and MRI Characteristics Indicative of Poor Prognosis
por: Boziki, Marina, et al.
Publicado: (2022) -
The Experience of a Tertiary Reference Hospital in the Study of Rare Neurological Diseases
por: Sintila, Styliani-Aggeliki, et al.
Publicado: (2023) -
CNS Ageing in Health and Neurodegenerative Disorders
por: Kesidou, Evangelia, et al.
Publicado: (2023) -
The Role of Diet and Interventions on Multiple Sclerosis: A Review
por: Stoiloudis, Panagiotis, et al.
Publicado: (2022) -
Long-Term Efficacy Outcomes of Natalizumab vs. Fingolimod in Patients With Highly Active Relapsing-Remitting Multiple Sclerosis: Real-World Data From a Multiple Sclerosis Reference Center
por: Boziki, Marina, et al.
Publicado: (2021)